2015 was another busy year in writing about new developments in treating retinal diseases. During the year, I published seven blog entries (and another four published articles - to be indexed separately). Here are the highlights of the blog writeups: Additional Marketing Approvals for Iluvien; A New Ophthalmic Application; and An Interesting Human Interest Story - January 7, 2015 Since I last wrote about Iluvien, Alimera Sciences and pSivida have announced additional marketing approvals for its use in treating chronic DME. The product is now approved for use in fourteen countries, including the U.S. In addition, pSivida is about to begin a Phase III study of its Medidur device for the treatment of uveitis, which should lead to a fast-track to approval. But the real reason for this update was the recently published story about how an eye doctor reached out to Paul Ashton, CEO of pSivida, to package an old HIV anti-viral, ganciclovir, in his drug delivery system, to save the sight of a ...